- Our Company
- News & Events
- Contact Us
Guardant360®-first testing is able to identify more patients who are eligible for targeted treatments than tissue-first testing. Here are the key findings from the NILE study reported earlier this year.
– Agreement between Guardant360® and tissue testing was greater than 90% for four biomarkers with FDA-approved therapies.
– Turnaround time was 6 days faster with Guardant360® vs. Standard Of Care tissue testing.
“In a landscape where a large fraction of our patients never get their tumor genotyped because of insufficient tissue or sequential tissue testing, it would make sense to adopt a strategy where blood is used first to detect alterations,” said Dr. Vassiliki A. Papadimitrakopoulou.
Watch this 2-minute video below to find out more about Guardant360®, the global leader in liquid biopsy.